SCHEMBL182841

SCHEMBL182841

COc1cccc(-c2ncnc3ccc(N(C)C)cc23)c1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 8/20 0.49
CYP1A2 P05177 8/20 0.49
CYP3A4 P08684 8/20 0.49
CYP2D6 P10635 7/20 0.49
CYP2C19 P33261 7/20 0.49
TSHR P16473 6/20 0.49
HPGD P15428 3/20 0.49
ALDH1A1 P00352 6/20 0.43
USP2 O75604 5/20 0.43
HSD17B10 Q99714 4/20 0.43
MAPK1 P28482 4/20 0.43
HIF1A Q16665 3/20 0.43
CYP2C9 P11712 3/20 0.43
KDM4E B2RXH2 2/20 0.43
TDP1 Q9NUW8 2/20 0.43
GLA P06280 2/20 0.43
MAPT P10636 1/20 0.43
HBB P68871 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MAP4K4 O95819 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL182803 0.72 MAP4K4 (0.54) LMNACYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL24010781 0.70 DOT1L (0.63) HPGDALDH1A1HSD17B10KDM4EGLA
SCHEMBL25828236 0.66 APP (0.51) LMNACYP1A2CYP3A4ALDH1A1HSD17B10
SCHEMBL4779108 0.66 IDO1 (0.43) LMNACYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL2993281 0.65 HSP90AA1 (0.44) LMNACYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL6182383 0.65 EGFR (0.56) EGFRKDRRETKITCSF1R
SCHEMBL10970553 0.65 MAP4K4 (0.51) LMNACYP1A2CYP3A4ALDH1A1HSD17B10
SCHEMBL8976460 0.65 EGFR (0.53) LMNACYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL196440 0.65 MGAM (0.55) LMNACYP3A4HPGDALDH1A1HSD17B10
SCHEMBL1264612 0.64 KIT (0.60) EGFRKDRKITCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2049502-B1 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2012-01-04 EP claimed